logo-loader
viewBiotec Pharmacon

Biotec Pharmacon strengthening market presence for its flagship Woulgan product

Christian Jorgensen, chief executive of Biotec Pharmacon (FRA:B4V),  talks Proactive London's Andrew Scott through the firm's two technology platforms - one of them's a unique enzymes platform where they sell to diagnostics and gene therapy companies.

The second platform is focused on BetaGlucens which develops and manufactures immune modulating compounds for the human health sectors. The technology's currently being used in a wound care product called Woulgan.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Commerical momentum at Applied Graphene Materials 'continues...

Applied Graphene Materials PLC's (LON:AGM) Adrian Potts tells Proactive London's Andrew Scott they're seeing positive traction among its customers and are enjoying ongoing momentum in its commercial pipeline. He says a restructuring process they're introducing will re-align the business to...

4 hours, 52 minutes ago

2 min read